Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron Added to Solifenacin in Incontinent Overactive Bladder Subjects
2012-005401-41Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- May 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mirabegron, solifenacin in overactive bladder (OAB), sponsored by Astellas Pharma. Started May 2013; status: completed.
02
Drugs
mirabegronsolifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2012-005401-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005401-41.